Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUXEDO-3: HER3-DXd in Breast/Lung Cancer Brain Metastases and Solid Tumor Leptomeningeal Disease
NCT05865990Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in breast cancer, non-small cell lung cancer (NSCLC) and solid tumor, sponsored by MEDSIR. Primary endpoints: Intracranial Objective Response Rate at 12 months and Overall Survival rate at 3 months. Started Nov 2023; status: completed.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05865990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05865990.